A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05536791
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇳🇱Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
🇪🇸Hospital Sant Joan de Déu, Barcelona, Spain
A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 77
- Registration Number
- NCT05520827
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 94
- Registration Number
- NCT05518708
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT05515328
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT05515588
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
- Conditions
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 99
- Registration Number
- NCT05512377
- Locations
- 🇩🇪
Klinikum der Universität München AÖR, München, Germany
🇩🇪Universitätsklinikum Ulm, Ulm, Germany
🇺🇸Southern Cancer Center, Mobile, Alabama, United States
Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT05503030
- Locations
- 🇬🇷
"ATTIKON" University General Hospital, Athens, Greece
🇬🇷University General Hospital of Heraklion, Heraklion, Greece
🇬🇷University General Hospital of Patra, Patra, Greece
Exacerbation Risk in Asthma
- Conditions
- Interventions
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1899
- Registration Number
- NCT05501639
- Locations
- 🇺🇸
eMax Health, White Plains, New York, United States
A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT05492994
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 66
- Registration Number
- NCT05471856
- Locations
- 🇯🇵
Saitama Medical University International Medical Center, Saitama, Hidaka, Japan
🇪🇸Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇪🇸Instituto Valenciano de Oncología, Valencia, Spain